Ciencia Research Publishes Cross-Nordic Study on Rare Blood Disease in Newborns
Kelvin Kwok, epidemiologist at our portfolio company Ciencia Research (formerly Schain Research), recently co-authored a study published in AJOG Global Reports on hemolytic disease of the fetus and newborn, a rare condition where a mother's immune system produces antibodies that attack her baby's red blood cells. The study was funded by Janssen Research & Development, part of Johnson & Johnson.
The study
Despite serious clinical consequences, large-scale data on the condition has been scarce. Kwok and his co-authors tackled that by linking nationwide health registries across Sweden, Finland, and Denmark to build a longitudinal cohort spanning more than two decades. The resulting dataset covers maternal characteristics, treatment patterns, and neonatal outcomes across thousands of affected pregnancies, revealing clinically meaningful differences in outcomes for the most severely affected newborns.
Why it matters
Building a study like this is harder than it sounds. Nordic health registries provide exceptional data: complete population coverage, decades of follow-up, and linkable records across hospitals, pharmacies, and demographic databases. But turning three countries' worth of registry data into a coherent, publishable study requires harmonising coding systems across registries that were never designed to talk to each other, navigating separate ethical review and data access processes in each country, and pooling enough cases across borders to produce meaningful results for a condition most individual hospitals rarely see.
Our investment thesis
Stella Capital invested in Ciencia because we believe the Nordic countries hold some of the most valuable health data infrastructure in the world, and that accessing it requires far more than analytical skill. It requires registry relationships, ethical review expertise, cross-border clinical collaboration, standardised methodologies, and secure data infrastructure to bring it all together. The Nordic RWE space has capable consultancies, but what global pharma and AI companies increasingly need is a repeatable platform for accessing this data, not a new consulting engagement every time.
That is what Ciencia is building. A peer-reviewed, three-country registry study commissioned by a top-ten global pharma company shows the model working: deep scientific expertise, delivered through infrastructure that can serve the next study too.
We think demand for this kind of capability will continue to grow as pharma and biotech companies look to real-world data to complement clinical trials, particularly in rare diseases and small populations where traditional trial designs face inherent constraints.